These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 28414925)

  • 21. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
    Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.
    Koczkowska M; Zuk M; Gorczynski A; Ratajska M; Lewandowska M; Biernat W; Limon J; Wasag B
    Cancer Med; 2016 Jul; 5(7):1640-6. PubMed ID: 27167707
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Lin KK; Harrell MI; Oza AM; Oaknin A; Ray-Coquard I; Tinker AV; Helman E; Radke MR; Say C; Vo LT; Mann E; Isaacson JD; Maloney L; O'Malley DM; Chambers SK; Kaufmann SH; Scott CL; Konecny GE; Coleman RL; Sun JX; Giordano H; Brenton JD; Harding TC; McNeish IA; Swisher EM
    Cancer Discov; 2019 Feb; 9(2):210-219. PubMed ID: 30425037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.
    Morse CB; Norquist BM; Harrell MI; Agnew KJ; Gray HJ; Urban RR; Garcia RL; Goff BA; Swisher EM
    Gynecol Oncol; 2016 Nov; 143(2):389-392. PubMed ID: 27575909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline mutations of the DNA repair pathways in uterine serous carcinoma.
    Frimer M; Levano KS; Rodriguez-Gabin A; Wang Y; Goldberg GL; Horwitz SB; Hou JY
    Gynecol Oncol; 2016 Apr; 141(1):101-7. PubMed ID: 27016235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
    Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
    Holý P; Hlaváč V; Šeborová K; Šůsová S; Tesařová T; Rob L; Hruda M; Bouda J; Bartáková A; Mrhalová M; Kopečková K; Al Obeed Allah M; Špaček J; Sedláková I; Souček P; Václavíková R
    Int J Cancer; 2024 Jul; 155(1):104-116. PubMed ID: 38447012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study.
    Daniels MS; Babb SA; King RH; Urbauer DL; Batte BA; Brandt AC; Amos CI; Buchanan AH; Mutch DG; Lu KH
    J Clin Oncol; 2014 Apr; 32(12):1249-55. PubMed ID: 24638001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-genome characterization of chemoresistant ovarian cancer.
    Patch AM; Christie EL; Etemadmoghadam D; Garsed DW; George J; Fereday S; Nones K; Cowin P; Alsop K; Bailey PJ; Kassahn KS; Newell F; Quinn MC; Kazakoff S; Quek K; Wilhelm-Benartzi C; Curry E; Leong HS; ; Hamilton A; Mileshkin L; Au-Yeung G; Kennedy C; Hung J; Chiew YE; Harnett P; Friedlander M; Quinn M; Pyman J; Cordner S; O'Brien P; Leditschke J; Young G; Strachan K; Waring P; Azar W; Mitchell C; Traficante N; Hendley J; Thorne H; Shackleton M; Miller DK; Arnau GM; Tothill RW; Holloway TP; Semple T; Harliwong I; Nourse C; Nourbakhsh E; Manning S; Idrisoglu S; Bruxner TJ; Christ AN; Poudel B; Holmes O; Anderson M; Leonard C; Lonie A; Hall N; Wood S; Taylor DF; Xu Q; Fink JL; Waddell N; Drapkin R; Stronach E; Gabra H; Brown R; Jewell A; Nagaraj SH; Markham E; Wilson PJ; Ellul J; McNally O; Doyle MA; Vedururu R; Stewart C; Lengyel E; Pearson JV; Waddell N; deFazio A; Grimmond SM; Bowtell DD
    Nature; 2015 May; 521(7553):489-94. PubMed ID: 26017449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
    Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
    Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1 mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma.
    Wang PH; Shyong WY; Li YF; Lee HH; Tsai WY; Chao HT; Wu CY; Tsai YC; Yuan CC
    Jpn J Clin Oncol; 2000 Aug; 30(8):343-8. PubMed ID: 11059339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    Zong H; Zhang J; Xu Z; Pan JN; Wang R; Han J; Jiang M; Ren R; Zang L; Wang H; Cao WM
    J Cancer; 2022; 13(4):1119-1129. PubMed ID: 35281878
    [No Abstract]   [Full Text] [Related]  

  • 35. High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
    Mazzuccato G; De Bonis M; Carboni V; Marchetti C; Urbani A; Scambia G; Capoluongo E; Fagotti A; Minucci A
    Mol Biol Rep; 2020 Jun; 47(6):4897-4903. PubMed ID: 32468256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
    Reyes MC; Arnold AG; Kauff ND; Levine DA; Soslow RA
    Mod Pathol; 2014 Oct; 27(10):1405-11. PubMed ID: 24577588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
    Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
    Choi MC; Hwang S; Kim S; Jung SG; Park H; Joo WD; Song SH; Lee C; Kim TH; Kang H; An HJ
    Cancer Res Treat; 2020 Apr; 52(2):634-644. PubMed ID: 32019284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
    Hussein YR; Ducie JA; Arnold AG; Kauff ND; Vargas-Alvarez HA; Sala E; Levine DA; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):404-9. PubMed ID: 26574845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
    Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.